Exercise to Boost Immunity in Advanced Cancer

The trial is a prospective feasibility trial conducted in Sheffield. Recruitment will include twenty patients receiving first line palliative immunotherapy for advanced, unresectable or metastatic mesothelioma and patients receiving first line systemic anti-cancer treatment for pancreatic cancer. Patients will attend the AWRC for a supervised exercise session once a week to include aerobic exercise along with an unsupervised weekly exercise session for 3 months. Blood samples will be collected at baseline and then monthly for 3 months, pre and post the supervised exercise session. Cytokine, myokine and immune cell concentration will be analysed using cytokine bead-based multiplex immune assays and RNA-seq to full profile changes in gene and protein expression

NCT Number	NCT06310993
Lead Sponsor	Sheffield Teaching Hospitals NHS Foundation Trust Collaborators: Sheffield Hallam University, University of Sheffield
Conditions	Mesothelioma; Lung, Pancreatic Cancer
Enrollment	30 participants
Start Date	2025-09-01
Primary Completion	2027-03-01 (estimated)
Study Completion	2027-03-01 (estimated)
Updated on ClinicalTrials.gov	2024-12-03